|
A new medicines trade and health security agenda for the European Commission |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
2017 Biosimilar Medicines Policy Overview: better access is crucial; tailored solutions essential for EU governments |
Medicines for Europe |
12 Sep 2017 |
Health & Consumers |
|
2018 – A year of unprecedented challenges and opportunities for pharmaceutical regulatory systems |
Medicines for Europe |
25 Jan 2018 |
Health & Consumers |
|
2022 Health at a Glance Report highlights the need to rethink investments in health after the COVID-19 pandemic |
Medicines for Europe |
05 Dec 2022 |
Health & Consumers |
|
62% of Medicines Dispensed in Europe are Generic, according to IMS New Data |
Medicines for Europe |
15 Jun 2017 |
Health & Consumers |
|
A DIGITAL FUTURE FOR VALUE ADDED MEDICINES – IQVIA publication shares the future of the sector |
Medicines for Europe |
24 Sep 2019 |
Health & Consumers |
|
Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries |
Medicines for Europe |
26 Nov 2021 |
Health & Consumers |
|
Access to medicines critical in European Parliament vote on EU IP action plan |
Medicines for Europe |
12 Nov 2021 |
Health & Consumers |
|
Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest |
Medicines for Europe |
14 Jun 2018 |
Health & Consumers |
|
Addressing medicine shortages in Europe: Competition is crucial for patient access |
Medicines for Europe |
29 Sep 2017 |
Health & Consumers, Competition |
|
Adjustments to IP framework needed to improve access to medicines in Europe |
Medicines for Europe |
16 Nov 2021 |
Science & Policymaking |
|
AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” |
Medicines for Europe |
03 Feb 2021 |
Health & Consumers |
|
Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe |
Medicines for Europe |
01 Oct 2021 |
Health & Consumers |
|
Billions more euros to re-invest in better healthcare thanks to biosimilar medicines |
Medicines for Europe |
14 Dec 2022 |
Health & Consumers |
|
Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health systems |
Medicines for Europe |
16 Dec 2021 |
Health & Consumers |
|
Biosimilar Medicines Opportunity: Dramatic Increase in Patient Access across Europe |
Medicines for Europe |
09 May 2017 |
Health & Consumers |
|
Biosimilar medicines: competition, sustainability and early* access on the agenda of DG GROW stakeholder workshop |
Medicines for Europe |
30 Oct 2019 |
Health & Consumers |
|
Biosimilar Medicines: essential for sustainable access to medicines |
Medicines for Europe |
27 Apr 2018 |
Health & Consumers |
|
Brexit - Life Science Industry Joint Position Paper |
Medicines for Europe |
14 Dec 2017 |
Health & Consumers, UK in Europe |
|
Central & Eastern European patients have inequitable access to medicines for life-threatening conditions |
Medicines for Europe |
25 Apr 2022 |
Health & Consumers |
|
CJEU decision on Gilead’s SPC on Truvada® leads to successful clarification in English court |
Medicines for Europe |
20 Sep 2018 |
Health & Consumers |
|
Commission sponsored study shows Supplementary Protection Certificate (SPC) Manufacturing Waiver will create Jobs, strengthen the pharmaceutical sector and reduce medicine costs |
Medicines for Europe |
18 Oct 2017 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
10 Dec 2021 |
Health & Consumers |
|
Competition policy essential for access to medicines |
Medicines for Europe |
29 Jan 2019 |
Health & Consumers |
|
Comprehensive SPC manufacturing waiver key for patient access to medicines, jobs and growth in Europe |
Medicines for Europe |
28 May 2018 |
Health & Consumers, Social Europe & Jobs |
|
COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy |
Medicines for Europe |
09 Jul 2020 |
Health & Consumers |
|
Crucial European Parliament vote vastly improves SPC manufacturing waiver |
Medicines for Europe |
24 Jan 2019 |
Health & Consumers |
|
Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies |
Medicines for Europe |
18 Sep 2020 |
Health & Consumers |
|
Driving local excellence, delivering European results |
Medicines for Europe |
06 Nov 2018 |
Health & Consumers |
|
Efficient use of pharmacovigilance data essential for patient safety |
Medicines for Europe |
30 Jan 2019 |
Health & Consumers |
